Supernus Pharmaceuticals(SUPN) - 2025 Q4 - Annual Results

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-35518 | 20-2590184 | | --- | --- | --- | | (State or other jurisdiction of incorporation | | (I.R.S. Employer Identification No.) | | or organization) | (Commission File Numb ...